Baseline MxA mRNA expression predicts interferon beta response in multiple sclerosis patients

Area of Science:

• Immunology
• Neuroscience
• Pharmacogenomics

Background:

• Myxovirus resistance protein A (MxA) is an interferon-induced molecule used to assess interferon-beta bioactivity.
• Limited data exists on the clinical utility of baseline MxA mRNA levels in predicting treatment outcomes.
• Multiple Sclerosis (MS) treatment with interferon-beta requires reliable predictors of patient response.

Purpose of the Study:

• To investigate the predictive value of baseline MxA mRNA expression for treatment response in MS patients.
• To determine if MxA mRNA levels can forecast disease relapse and progression during interferon-beta therapy.

Main Methods:

• Real-time PCR was used to quantify MxA mRNA in baseline blood samples from 104 MS patients before interferon-beta initiation.
• Demographic and clinical data were prospectively collected to categorize patients as responders or non-responders.
• Receiver Operating Characteristic (ROC) analysis and survival analysis were employed to establish predictive thresholds and assess outcomes.

Main Results:

• Significantly lower baseline MxA mRNA expression was observed in responders compared to non-responders (p<0.0001).
• An MxA mRNA threshold of 1.096 effectively differentiated responders (73.9% sensitivity, 69.0% specificity).
• Lower MxA titers correlated with significantly longer time to relapse (p<0.0001) and EDSS progression (p=0.01).

Conclusions:

• Baseline MxA mRNA levels serve as a potential biomarker for predicting interferon-beta treatment response in multiple sclerosis.
• Assessing pre-treatment MxA mRNA expression may aid in personalizing MS therapy selection.
• This finding highlights the role of innate immune responses in predicting therapeutic efficacy in MS.